Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring form of non-Hodgkin lymphoma (NHL), accounting for approximately one-third of adult lymphomas. There was an unprecedented rise in NHL incidence (3-4 % per year) from the 1970s to the mid-1990s, comparable only to the rise in skin cancers. 1 It is estimated that there will be 70,140 new NHL cases in 2012, making NHL the seventh most common cancer. 2 DLBCL most commonly presents in the sixth decade, but there is some racial variation in the age of onset, with white Americans presenting at a mean age of 64 compared with a mean age of 54 for black patients.
tool to predict outcome for patients with DLBCL.
14 In addition to age, clinical features that were predictive of overall survival (OS) and relapse-free survival were derived from a pooled analysis of more than 2,000 patients with aggressive lymphoma (mainly DLBCL) treated with an anthracycline-containing chemotherapy regimen. These factors include advanced disease stage, elevated serum lactate dehydrogenase, poorer performance status, and a number of extranodal disease sites ≥2. Patients are scored based on the presence of these clinical features and can then be risk-stratified into one of four discrete prognostic groups, with five-year predicted survival rates of 73, 51, 43, and 26 %, respectively. A more recent analysis of more than 1,000 patients treated with chemoimmunotherapy suggests that IPI maintains its relevance in the rituximab era and remains a valid prognostic tool. 15 An alternative index, the Elderly IPI (E-IPI), with an age cut-off of 70 years rather than 60, has been reported to provide better discrimination of outcome for patients >60 years with DLBCL treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). 16 These findings were recently validated when the conventional IPI and the E-IPI were compared in the RICOVER-60 data set. Both the IPI and E-IPI provided prognostic discrimination for OS;
however, the E-IPI outperformed the conventional IPI. 17 Although age is a relevant clinical predictor of outcome, is it a reflection of a patient's overall clinical status or is it related to an intrinsic biological feature of the tumor? Over the past decade, there have been significant efforts to define biologically relevant subgroups of DLBCL.
Gene-expression profiling (GEP) from DNA microarrays has delineated expression patterns that reflect differences in cell of origin, proliferation rate, and host immune response to the tumor. 18 DLBCL can now be subdivided using GEP into at least three molecular subtypes: activated B-cell-like (ABC), germinal center B-cell-like (GCB), and primary mediastinal large B-cell lymphoma. The ABC and GCB signatures are biologic determinants of prognosis in patients treated with chemoimmunotherapy, independent of IPI, with the GCB subtype having a significantly better five-year survival rate than ABC DLBCL (OS 60 versus 35 %, p<0.001).
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Whether there is a relationship between aging and the distribution of these two gene expression profiles has not been clearly defined.
Rosenwald et al. reported a trend toward a higher proportion of ABC subtypes in patients over the age of 60 years. 20 A retrospective analysis studied this further. GEP was performed on 131 de novo DLBCL patients >50 years of age (median 68 years, range 50-91) and reported a significant increase in ABC subtypes in proportion to increasing age. 21 To strengthen these results, a similar analysis was done on data accessed from the Lenz study. 22 The investigators found a similar increase in the proportion of ABC subtypes associated with age (average increase of 13.7 % in ABC for every 10 years after the age of 50, versus 7.5 % in the Lenz series). 21 In contrast to adults, children with DLBCL have excellent prognosis. Oschlies et al. found a striking predominance of GCB subtypes in 63 cases of pediatric DLBCL, which may explain their better outcomes and again suggests a relationship between DLBCL subtype distribution and age. 23 To counter these claims, a retrospective analysis of very elderly patients (>80 years) reported that clinical and biologic characteristics of older patients with lymphoma at presentation are similar to those of younger ones, but there were significant differences in disease management. 9 No specific chromosomal or genetic abnormalities have been described in elderly patients; however, the majority of studies have been focused on defining the level of heterogeneity between different subtypes, not heterogeneity between age groups. Further speculation on the pathogenesis of poor prognosis in elderly patients with DLBCL includes the finding that B-cell diversity decreases dramatically with age, and this loss of diversity is characterized by clonal expansion of B-cells in vivo.
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A well recognized predisposing risk factor for the occurrence of NHL is immunosuppression. 25 Host factors that have been implicated in this increased risk include a high prevalence of the Epstein-Barr virus (EBV) and defects in immune regulation with resultant cytokine production.
EBV-related DLBCL is almost exclusively reported in the elderly, including in very old patients, and portends a poor prognosis with a median survival of two years. 26 Further study into the relationship between age and tumor biology is warranted.
Assessing Therapeutic Options for Elderly Patients
One of the challenges faced with this particular patient population are the age-related factors that must be considered when discussing treatment options with patients. It is well-known that with increasing age, the likelihood of comorbid disease also increases. For example, in one survey, 61 % of the patients aged 70 years or older had at least one comorbid condition, compared with 20 % of patients younger than 60 years. 27 Of particular importance is the prevalence of heart disease, which may hinder therapeutic options such as anthracyclines. Comorbid conditions also frequently result in polypharmacy. Elderly patients may have alterations in drug absorption, distribution, metabolism, and clearance, which change the pharmacodynamics of therapeutic agents, and attention to the appropriate dosing of drugs is imperative. 28 Hematopoietic reserve is also different from younger patients and myelotoxicity can be increased with standard regimens. 29 Determining performance status, though subjective, carries prognostic implications. Assessing the degree of functional dependence and frailty in elderly patients is also important. Age and performance status are currently the most frequently used criteria to select patients for standard chemotherapy, but the final decision is generally left to the clinical judgment of the treating physician. 30 There is a large body of geriatric literature that tries to address this problem of subjectivity by designing specific comprehensive geriatric assessment scores as more 40 The benefits of R-CHOP in older patients was confirmed by a US Intergroup trial, which randomized patients to R-CHOP-21 or CHOP-21, with a second randomization of responders to maintenance R or observation.
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The three-year failure-free survival rate was 53 % for R-CHOP patients and 46 % for CHOP patients (p=0.04) and no benefit was seen with maintenance R in the R-CHOP arm. Based on these and other data, R-CHOP has been well established as the standard induction regimen in DLBCL.
Given the improvement in outcomes with the addition of R, the German High Grade Non-Hodgkin Lymphoma Study Group explored a dose-intense regimen incorporating R based on previous data demonstrating improved outcomes in older patients treated with CHOP given every 14 days (CHOP-14). 43 The RICOVER-60 trial randomized elderly The majority of deaths (57 %) were secondary to lymphoma progression, 12 of 58 (21 %) deaths were attributed to treatment toxicity. The most frequent side effect was hematological toxicity (grade ≥3 neutropenia 40 %, febrile neutropenia 7 %). Prophylactic G-CSF was left to the discretion of the treating physician. However, in the event of severe neutropenia or neutropenic fever, G-CSF was recommended from day 6-13 of the subsequent cycle or until neutrophils were ≥1.0×109/l.
In a multivariate analysis, the only parameter associated with worse outcome was low serum albumin concentration. Included in the initial assessment was the instrumental activities of daily living scale. Without systematic comparison and in the absence of a control arm, this study suggests that in selected patients older than 80 years with a good performance status (0-2), R-miniCHOP offers a compromise between efficacy and safety. However, PFS and OS at two years in this trial were lower than would be expected for standard CHOP-21 in patients >60 years, thus this approach would benefit from a comparison with standard CHOP-21 in this population, given that most deaths were due to lymphoma progression.
Future Directions
Prospective studies directed at elderly patients are needed, particularly for guiding treatment decisions. A particular area of need is the relapsed or refractory setting. Younger patients who experience relapse will be evaluated for salvage therapy and high-dose therapy (HDT) with autologous stem cell transplant (ASCT 54 Overexpression of NF-κB is a potential target of the ABC subtype of DLBCL, and bortezomib has been used to exploit this concept. 55 Lenalidomide has shown significant activity in relapsed DLBCL, with higher responses also seen in the non-GCB subtype. 56 As discussed, these strategies hold promise for elderly patients, as most appear to have limited toxicity or toxicity that does not overlap considerably with prior chemotherapy.
Conclusions
Although a number of retrospective analyses have been performed reporting outcomes in elderly patients, prospective data are limited.
With the aging population, the prevalence of DLCBL, particularly in elderly patients, is expected to increase. Future research is needed not only to address treatment strategies but also to define the biologic heterogeneity between younger and older patients with DLBCL, so that more rational therapeutic design can be investigated. Several issues arise when addressing worse outcomes seen with elderly patients compared with their younger counterparts. Elderly patients often have more comorbid illnesses, worse performance status, less hematologic reserve, and altered pharmacokinetics related to decreased metabolism and clearance of drugs. Clinical judgment clearly contributes to determination as to whether patients are fit for aggressive treatment.
Since it is well established that aggressive chemoimmunotherapy can provide cure to elderly patients, what is needed are objective tools to identify patients who will safely benefit from aggressive therapy. 
